ArticleEndocrine connections2017
Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.
Article in Endocrine connections, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Multiple Therapeutic Applications of Metformin Moving Beyond Its Anti-Diabetic Role: A Systematic Review.Journal of the ASEAN Federation of Endocrine Societies · 2025Pooled it
- Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.International journal of obesity (2005) · 2025 · on this mapPooled it
- Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials.Scientific reports · 2025Pooled it
- Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.BMC endocrine disorders · 2019 · on this mapPooled it
- Review
- Review
- Modern Polycystic Ovary Syndrome (PCOS) Management: Intelligent Drug Delivery and Metabolic Reprogramming for Ovarian Restoration and Fertility Optimization.Biomolecules · 2026Review
- Balancing metabolic optimization and reproductive safety in Polycystic Ovary Syndrome: a Bayesian-informed framework for GLP-1 receptor agonists.Frontiers in nutrition · 2026Review
- Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries.JBRA assisted reproduction · 2025Review
- Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review.Seminars in thrombosis and hemostasis · 2025Review
- Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials.Diabetology & metabolic syndrome · 2025Article
- Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Article
- Possible Effect of Polycystic Ovary Syndrome (PCOS) on Cardiovascular Disease (CVD): An Update.Journal of clinical medicine · 2024Review
- Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?Journal of endocrinological investigation · 2023Review
- Polycystic ovary syndrome: pathophysiology and therapeutic opportunities.BMJ medicine · 2023Review
- Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives.Biomedicines · 2022Review
- Unravelling Polycystic Ovary Syndrome and Its Comorbidities.Journal of obesity & metabolic syndrome · 2021Review
- Article
- Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on markers of VTE and CVD risk, in PCOS. In a double-blind, placebo-controlled, randomized trial, 72 overweight and/or insulin-resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference in change (baseline to follow-up) in plasminogen activator inhibitor-1 levels and in thrombin generation test parameters: endogenous thrombin potential, peak thrombin concentration, lag time and time to peak. Mean weight loss was 5.2 kg (95% CI 3.0-7.5 kg,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.